OncoMatch/Clinical Trials/NCT06081686
Study of [177Lu] Lu-XT033 Injection in Patients With Metastatic Prostate Cancer
Is NCT06081686 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Phase I:[177Lu]Lu-XT033 and Phase II:[177Lu]Lu-XT033 for prostate cancer.
Treatment: Phase I:[177Lu]Lu-XT033 · Phase II:[177Lu]Lu-XT033 — This was a multicenter, open-label, phase I/II study to evaluate the safety and tolerability, radiation dosimetry and pharmacokinetic characteristics, and efficacy of \[177Lu\] Lu-XT033 injection in patients with metastatic prostate cancer, including a phase I study and a phase II extension study.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: novel androgen axis drug (enzalutamide, abiraterone)
Patients must have received at least one NAAD (such as enzalutamide and/or abiraterone)
Must have received: taxane
Patients must have been previously treated with at least 1, but no more than 2 previous taxane regimens
Cannot have received: PSMA-targeted radioligand therapy
Previous PSMA-targeted radioligand therapy is not allowed
Cannot have received: bone-targeted radionuclide therapy (Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223)
Exception: within 6 months of enrollment
Previous treatment with any of the following within 6 months of enrollment: Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223, hemi-body irradiation
Cannot have received: systemic anti-cancer therapy
Exception: within 28 days prior to day of enrollment
Any systemic anti-cancer therapy (e.g. chemotherapy, immunotherapy or biological therapy) within 28 days prior to day of enrollment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify